Overview

A Study of GB261 in Systemic Sclerosis

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of GB261 in patients with SSc.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Ruijin Hospital